Karyopharm CFO logs tax-related sale of 1,626 shares

Karyopharm Therapeutics executive Lori Macomber reported an automatic tax-related stock sale.

Rhea-AI Filing Summary

Karyopharm Therapeutics executive Lori Macomber reported an automatic tax-related stock sale. On 02/03/2026, the EVP, CFO & Treasurer sold 1,626 shares of Karyopharm Therapeutics Inc. common stock at $6.30 per share in a broker-assisted transaction tied to restricted stock unit vesting. After the sale, she directly beneficially owned 85,105 common shares. The filing explains the transaction was executed under a durable automatic sale instruction plan adopted on December 19, 2024, solely to cover withholding tax liabilities and did not represent a discretionary trade.

Insider Trade Summary

Net Seller: 1,626 shares

Net Sell 1 txn

Insider Macomber Lori

Role EVP, CFO & Treasurer

Sold 1,626 shs ($10K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,626	$6.30	$10K

Holdings After Transaction: Common Stock — 85,105 shares (Direct)

Footnotes (1)

1. F1. This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on December 19, 2024, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Karyopharm (KPTI) report for Lori Macomber?

Karyopharm reported that EVP, CFO & Treasurer Lori Macomber sold 1,626 shares of common stock at $6.30 on February 3, 2026. The sale was part of a broker-assisted transaction related to restricted stock unit vesting, not a discretionary open-market trade.

Why did Karyopharm (KPTI) executive Lori Macomber sell 1,626 shares?

The 1,626-share sale by Lori Macomber was executed to cover withholding tax liability from the vesting of restricted stock units. It was carried out under a durable automatic sale instruction plan, meaning it was a pre-arranged, non-discretionary transaction rather than a voluntary timing decision.

How many Karyopharm (KPTI) shares does Lori Macomber own after this Form 4?

Following the reported transaction, Lori Macomber beneficially owned 85,105 shares of Karyopharm common stock directly. This figure reflects her holdings after the 1,626 shares were sold in connection with the tax withholding related to restricted stock unit vesting.

Was the Karyopharm (KPTI) insider sale by Lori Macomber discretionary?

The sale was not discretionary. The filing states it was executed under a durable automatic sale instruction plan adopted December 19, 2024. Shares were sold via a broker-assisted transaction specifically to satisfy tax withholding obligations from restricted stock unit vesting.

What is a durable automatic sale instruction plan in the KPTI Form 4?

In this context, a durable automatic sale instruction plan is a pre-established arrangement under which shares are sold automatically. For Lori Macomber, it directed a broker-assisted sale of Karyopharm shares to cover tax withholding from restricted stock unit vesting, without day-to-day trading discretion.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/04/2026 - 04:11 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Macomber Lori

(Last) (First) (Middle)

C/O KARYOPHARM THERAPEUTICS INC.

85 WELLS AVENUE

(Street)

NEWTON MA 02459

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Karyopharm Therapeutics Inc. [ KPTI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, CFO & Treasurer

3. Date of Earliest Transaction (Month/Day/Year)
02/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/03/2026		S(1)		1,626	D	$6.3	85,105	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on December 19, 2024, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

	/s/ Nancy Smith as Attorney-in-Fact for Lori Macomber	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.